false 0001821825 0001821825 2024-06-04 2024-06-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 4, 2024

 

Organon & Co.

(Exact name of registrant as specified in its charter)

 

Delaware    001-40235    46-4838035
(State or other jurisdiction    (Commission    (I.R.S. Employer
of incorporation)    File Number)   Identification No.)
               
30 Hudson Street, Floor 33,
Jersey City, NJ 		         07302
(Address of principal executive offices)          (Zip Code)

 

Registrant’s telephone number, including area code: (551) 430-6900

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.01 per share   OGN   NYSE

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

  

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On June 4, 2024, Organon & Co. (the “Company”) held its 2024 Annual Meeting, at which the Company’s shareholders considered three (3) proposals, each of which is described in more detail in the Company’s proxy statement filed with the U.S. Securities and Exchange Commission on April 25, 2024 (the “Proxy Statement”). There were 257,172,661 outstanding shares entitled to vote and there were 221,544,166 shares present in person or by proxy at the 2024 Annual Meeting, representing approximately eighty-six percent (86%) of the shares outstanding and entitled to vote. The voting results are presented below.

 

1. To elect the four (4) Class III directors nominated by the Company’s Board of Directors to serve until the 2025 annual meeting of Organon’s shareholders or until a successor has been duly elected and qualified.

 

Nominee  For   Against   Abstain   Broker Non-Votes1 
Kevin Ali  176,343,603   2,212,837   354,540   42,633,186 
Martha E. McGarry  173,247,544   5,347,655   315,781   42,633,186 
Philip Ozuah, M.D., Ph.D.  174,355,642   4,214,516   340,822   42,633,186 
Shalini Sharp  176,315,828   2,258,415   336,737   42,633,186 

 

2. To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement.

 

For   Against   Abstain   Broker Non-Votes1 
 149,712,445   28,201,528   997,007   42,633,186 

 

 

3. To ratify the appointment by the Company’s Audit Committee of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.

 

For   Against   Abstain   Broker Non-Votes1 
 219,810,374   966,483   767,309   0 

 

 

 

1 A broker-non vote occurs when a broker, bank, or other nominee holding shares for a beneficial owner does not vote on a particular proposal because the nominee does not have the discretionary voting power with respect to the item and has not received voting instructions from the beneficial owner of the shares it holds. Broker non-votes are counted when determining whether the necessary quorum of shareholders is present or represented at each annual meeting.

  

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

  Organon & Co.
   
  By: /s/ Kirke Weaver
    Name: Kirke Weaver
    Title: General Counsel and Corporate Secretary

 

Dated: June 6, 2024

 

 

 

v3.24.1.1.u2
Cover
Jun. 04, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 04, 2024
Entity File Number 001-40235
Entity Registrant Name Organon & Co.
Entity Central Index Key 0001821825
Entity Tax Identification Number 46-4838035
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 30 Hudson Street
Entity Address, Address Line Two Floor 33
Entity Address, City or Town Jersey City
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07302
City Area Code 551
Local Phone Number 430-6900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol OGN
Security Exchange Name NYSE
Entity Emerging Growth Company false
Grafico Azioni Organon (NYSE:OGN)
Storico
Da Dic 2024 a Gen 2025 Clicca qui per i Grafici di Organon
Grafico Azioni Organon (NYSE:OGN)
Storico
Da Gen 2024 a Gen 2025 Clicca qui per i Grafici di Organon